跳至主要内容
临床试验/NCT07398807
NCT07398807招募中1 期

Effectiveness of Combining Micro Needling With 5 Fluorouracil Versus Potent Topical Steroids; in Treating Limited Vitiligo- Randomised Controlled Study

Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年8月8日最近更新:
干预措施

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
40
试验地点
1
主要终点
Re-pigmentation of vitiligo patches of patients treated with 5FU with micro-needling versus potent topical steroids at week 12 as assessed by decrease in VASI (Vitiligo Area Scoring Index) scores, ranging from score 0 to 100.

研究概览

简要总结

The goal of this clinical trial is to learn how well 5 fluorouracil (5FU) with micro-needling works to treat limited vitiligo as compared to strong steroid applied on skin. It will also learn about the safety of both these treatments. The main questions it aims to answer are:

  • How well does 5FU with microneedling work to treat vitiligo by returning pigmentation in vitiligo patches as compared to steroid?
  • What is participant's satisfaction when treated with 5FU with microneedling as compared to steroid?
  • What skin problems do participants have when treated with FU with microneedling and steroid?

Researchers will compare 5FU with microneedling to steroid application to see how well both work to return pigment in vitiligo patches.

Participants will be divided into two groups. For Group A, 5 FU will be rubbed and absorbed on the vitiligo patch after micro-needling every 2 weeks.

For group B, topical 0.05% clobetasol propionate ointment will be applied twice a day on the vitiligo patches for 12 weeks.

Vitiligo patches will be assessed at the start of trial and then after 12 weeks of treatment.

详细描述

The rationale of this study is to find a cost-effective treatment regime of 5 fluorouracil for limited stable vitiligo. We aim to compare how effective is the combination of micro-needling with 5 Fluorouracil versus topical potent steroids in the cases of stable, limited vitiligo (< 10% body surface area -BSA).

40 patients with limited vitiligo consulting the dermatologist in the hospital OPD will be included in the trial after application of the mentioned inclusion and exclusion criteria. After informed consent, a dermatologist will explain the required details of the procedure to the patients and give them their required treatment plan. They will be randomized into two groups by lottery method.

Demographic data like age, gender, location and number of vitiligo patches will be recorded along with baseline photograph and measurement of the vitiligo patches by VASI score.

In first group i.e., Group A, a topical eutectic mixture of local anesthetic in cream formulation (EMLA) will be applied over the patient's lesions for 30- 45 minutes. Lesion will be cleaned by pyodine iodine applied for at least 5 minutes. Micro-needling will be done by dr. Pen Ultima A6 with 42 needle cartridges (single usage) with 3mm depth and 2 passes will be made on the effected patch of vitiligo. Sterile gauze will be pressed on the lesion for 2 minutes to stop bleeding. Afterwards depth will be decreased to 1.5mm and 5 FU will be rubbed on the lesion before this step. Aim would be to facilitate percutaneous absorption of the drug with micro-needling. Micro-needling device will be held at 90-degree angle and will be glided up and down, followed by side to side and then diagonal sections with light pressure to avoid dragging. Few drops of 5 FU will be rubbed and absorbed again on the vitiligo patch after micro-needling. Not more than 0.5 ml 5FU will be used during each session. Lesions will be covered by a sterile dressing after the procedure. It will be removed after 12 hours. Patient will be instructed to avoid bathing for 24 hours after the procedure. 6 sessions will be done at 2 weeks interval.

Group B will be advised topical 0.05% clobetasol propionate ointment twice a day on the vitiligo patches.1 finger-tip unit (FTU) will be used for 2% BSA i.e., 0.5 grams. The application should be continued for 12 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
4 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients willing to participate in the study
  • Patients of age group of 05 -70 years.
  • Vitiligo involving less than or equal to 10% body surface area.

排除标准

  • Patients using or have used other treatments for vitiligo
  • Pregnant women or lactating women
  • Patients with unstable vitiligo
  • Patients on immunosuppressant medications due to other diseases
  • Patients having anemia, immunosuppression, bleeding disorder, taking anticoagulants or anti-platelet drugs or having epilepsy
  • Patient having history of keloids or hypertrophic scars
  • Patients with history of hypersensitivity to either of the drugs

研究组 & 干预措施

Microneedling with topical 5-fluorouracil

Experimental

干预措施: Microneedling with 5-fluorouracil (Drug)

Clobetasol propionate 0.05%

Active Comparator

干预措施: Topical application of 0.05% Clobetasol propionate (Drug)

结局指标

主要结局

Re-pigmentation of vitiligo patches of patients treated with 5FU with micro-needling versus potent topical steroids at week 12 as assessed by decrease in VASI (Vitiligo Area Scoring Index) scores, ranging from score 0 to 100.

时间窗: From enrollment to the end of treatment at 6 months

次要结局

未报告次要终点

研究者

发起方
Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan
申办方类型
Other
责任方
Principal Investigator
主要研究者

Sara Khan

Principal investigator

Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan

研究点 (1)

Loading locations...

相似试验